CRISPR/Cas9 fight could be far from over – Seeking Alpha
BioWorld Online |
CRISPR/Cas9 fight could be far from over
Seeking Alpha *Despite the initial reaction from investors that stoked Wednesday's nearly 30% spike in Editas Medicine (NASDAQ:EDIT), the dispute over who owns what related to patents covering gene editing technology CRISPR/Cas9 could drag on for some time. Editas Medicine Inc (NASDAQ:EDIT) Reports USPTO Decision Positive To Broad Institute In CRISPR Intervention |
